In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Unprecedented PRESERVE IVC Filter Study Unites Surgeons, Interventionalists, Manufacturers, And The FDA

Executive Summary

An unprecedented clinical trial called PRESERVE is bringing together the Society of Interventional Radiology, the Society for Vascular Surgery, major manufacturers of inferior vena cava filters, and the FDA to answer questions about how the filter might best fit into modern medicine.

You may also be interested in...



More Bad News About IVC Filters From National Database Study

A nationwide observational study found that adjunctive inferior vena cava filter placement in patients undergoing catheter-directed thrombolysis does not reduce in-hospital mortality, but increases inpatient charges and length of stay. One-third of all patients undergoing catheter-directed thrombolysis receive IVC filters.

Novate: Re-Newing The IVC Filter Market

Serial medtech entrepreneurs Chas Taylor and Paul Gilson founded Novate Medical Ltd. to develop a bioconvertible inferior vena cava filter – it protects patients from pulmonary embolisms during a critical interval, then integrates into the vessel wall. There is no need to retrieve it, a benefit that goes far beyond the economics of avoiding a second procedure.

Finance Watch: Two SPAC Deals, Two IPOs Take Four Biopharmas Public

Public Company Edition: Mergers with special purpose acquisition corporations may be heating up, but in addition to the Surrozen and Tango SPAC deals Recursion and Biomea launched initial public offerings. Also, Organon sells $5.6bn worth of notes to fund spinout from Merck & Co.

Topics

Related Companies

UsernamePublicRestriction

Register

IV004090

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel